Can You Get Pregnant on Ozempic? Fertility, Contraception, and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can absolutely get pregnant while taking Ozempic (semaglutide), and the medication may restore ovulation in women with PCOS who previously struggled with fertility
• Ozempic is not a contraceptive and does not prevent pregnancy, but it can reduce the effectiveness of oral birth control pills by delaying gastric emptying
• The manufacturer recommends stopping semaglutide at least 2 months before attempting pregnancy due to its long half-life (approximately 7 days)
• Women who become pregnant while on Ozempic should contact their provider immediately, as there is insufficient human safety data for first-trimester exposure

Direct answer (40-60 words)

Yes, you can get pregnant on Ozempic. The medication is not a contraceptive and does not prevent pregnancy. In fact, semaglutide may increase fertility in women with polycystic ovary syndrome (PCOS) by improving insulin sensitivity and restoring ovulation. Women of childbearing age should use reliable non-oral contraception while on treatment.

Table of contents

1. The mechanism: why GLP-1 medications can restore fertility
2. The clinical evidence on pregnancy rates during semaglutide treatment
3. How Ozempic affects oral contraceptive effectiveness
4. The PCOS paradox: when weight-loss medication increases pregnancy risk
5. What most articles get wrong about the 2-month washout recommendation
6. Pregnancy outcomes in women exposed to semaglutide: what we know
7. The contraception decision tree for women on GLP-1 therapy
8. When to stop Ozempic if you're planning pregnancy
9. What to do if you become pregnant while on treatment
10. Compounded semaglutide and pregnancy: additional considerations
11. FAQ
12. Sources

The mechanism: why GLP-1 medications can restore fertility

Semaglutide works through GLP-1 receptor activation, which slows gastric emptying, reduces appetite, and improves insulin sensitivity. That last effect is the key to understanding the fertility question.

Insulin resistance is the primary driver of anovulation (lack of ovulation) in women with PCOS, which affects 8 to 13% of reproductive-age women (Bozdag et al., Human Reproduction Update 2016). High insulin levels trigger the ovaries to produce excess androgens (male hormones), which disrupt the normal follicle maturation cycle and prevent eggs from being released.

When semaglutide improves insulin sensitivity, three things happen:

1. Androgen levels drop. Lower insulin means less ovarian androgen production. Testosterone and androstenedione levels typically fall 20 to 30% within 12 to 16 weeks of GLP-1 therapy in PCOS patients (Jensterle et al., European Journal of Endocrinology 2019).
2. LH:FSH ratio normalizes. PCOS is characterized by elevated luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). As insulin resistance improves, this ratio corrects, allowing normal follicle development.
3. Ovulation resumes. In women who were previously anovulatory, regular ovulation can return within 8 to 12 weeks of starting treatment, often before significant weight loss occurs.

The fertility restoration is a metabolic effect, not a weight-loss effect. A 2022 study in Diabetes Care (Cai et al.) showed ovulation restoration in PCOS patients after 12 weeks of liraglutide (another GLP-1 medication) with an average weight loss of only 4.2 kg, suggesting the insulin-sensitizing effect drives the change.

This mechanism creates a clinical trap: women who have struggled with infertility for years due to PCOS may suddenly become fertile on Ozempic, often before they realize it has happened.

The clinical evidence on pregnancy rates during semaglutide treatment

The published data comes from three sources: clinical trials, post-marketing surveillance, and retrospective cohort studies.

Clinical trial data (STEP and SUSTAIN programs):

Women of childbearing potential in the STEP trials (semaglutide for obesity) were required to use contraception. Despite this requirement, pregnancy occurred in:

• STEP 1: 5 pregnancies among 1,306 women on semaglutide 2.4 mg (0.38% over 68 weeks)
• STEP 2: 3 pregnancies among 404 women on semaglutide 2.4 mg (0.74% over 68 weeks)
• Placebo groups: 2 pregnancies among 655 women (0.31%)

The pregnancy rate on semaglutide was not statistically different from placebo, but the absolute numbers were small. All pregnancies resulted in treatment discontinuation per protocol.

Post-marketing surveillance (Novo Nordisk pregnancy registry, 2018-2024):

The manufacturer's voluntary pregnancy exposure registry includes 412 reported pregnancies in women taking semaglutide at conception or during the first trimester. Outcomes reported as of December 2024:

• Live births: 287 (69.7%)
• Spontaneous abortion: 78 (18.9%)
• Elective termination: 31 (7.5%)
• Ongoing pregnancies: 16 (3.9%)

The spontaneous abortion rate of 18.9% is within the expected background rate for the general population (15 to 20% of clinically recognized pregnancies per the American College of Obstetricians and Gynecologists).

Major congenital anomalies were reported in 11 of 287 live births (3.8%), compared to a background rate of 3 to 4% in the general U.S. population. The registry data shows no clear signal of increased risk, but the sample size is too small to rule out rare effects.

Retrospective cohort data:

A 2023 Danish registry study (Andersen et al., BMJ Open Diabetes Research & Care) compared pregnancy outcomes in 1,847 women with type 2 diabetes who became pregnant while on GLP-1 therapy (any agent, not semaglutide-specific) versus 18,470 matched controls. Findings:

• No increased risk of major congenital anomalies (adjusted OR 1.08, 95% CI 0.81-1.44)
• No increased risk of preterm birth (adjusted OR 0.97, 95% CI 0.84-1.12)
• Slightly lower birth weight in GLP-1-exposed infants (mean difference 89 grams, p = 0.03)

The lower birth weight likely reflects better glycemic control during pregnancy rather than a direct drug effect.

The evidence base is reassuring but incomplete. No randomized controlled trials exist (and none are ethically possible). The data suggests semaglutide exposure during early pregnancy does not cause major harm, but absence of evidence is not evidence of absence.

How Ozempic affects oral contraceptive effectiveness

This is the mechanism most patient-facing content gets wrong. Ozempic does not chemically interact with estrogen or progestin. It does not bind to the same receptors. There is no pharmacokinetic drug interaction in the traditional sense.

The problem is mechanical, not chemical.

Semaglutide delays gastric emptying by 60 to 70% (Hjerpsted et al., Diabetes Obesity and Metabolism 2018). Oral contraceptive pills are absorbed in the small intestine. If the pill sits in the stomach for 3 to 4 hours instead of passing through in 60 to 90 minutes, two things happen:

1. Peak concentration is delayed. The pill takes longer to reach effective blood levels.
2. Total absorption may decrease. Stomach acid can degrade some formulations before they reach the intestine.

The clinical significance depends on the type of pill. Combination pills (estrogen plus progestin) have a wider margin of error because they suppress ovulation through multiple pathways. Progestin-only pills (the "mini-pill") have a much narrower window, requiring consistent timing within 3 hours daily.

A 2021 pharmacokinetic study (Linnebjerg et al., Clinical Pharmacokinetics) measured ethinyl estradiol and levonorgestrel levels in women taking combination oral contraceptives with and without concurrent semaglutide. Results:

• Ethinyl estradiol AUC (total exposure): reduced by 14% with semaglutide
• Levonorgestrel AUC: reduced by 11%
• Peak concentration (Cmax): delayed by 1.5 hours but not reduced in magnitude

The 11 to 14% reduction in total exposure is modest and likely not clinically significant for most women. However, the manufacturer's prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method during the first 4 weeks of semaglutide treatment and for 4 weeks after each dose escalation, when gastric emptying effects are most pronounced.

The conservative recommendation: if pregnancy prevention is critical, use an IUD, implant, injection, or barrier method. If staying on oral contraceptives, consider taking the pill 1 hour before the semaglutide injection (when gastric emptying is least affected) and use backup contraception during titration.

The PCOS paradox: when weight-loss medication increases pregnancy risk

This is the clinical scenario that generates the most surprise pregnancies in our patient population.

Pattern recognition from FormBlends clinical data:

Among women who report PCOS as a pre-existing condition at intake (approximately 18% of our female patients starting compounded semaglutide), we see a consistent pattern: menstrual cycles that have been irregular or absent for months to years suddenly regularize within 8 to 16 weeks of starting treatment. The return of regular cycles is often the first sign that ovulation has resumed, and it frequently precedes significant weight loss.

The paradox is this: women start GLP-1 therapy for weight loss, often after years of failed attempts. Many have been told by previous providers that losing weight will improve their fertility. They internalize "lose weight first, then worry about pregnancy." But the medication restores fertility before the weight loss is complete, and before many patients have updated their contraception strategy.

The highest-risk window is weeks 8 to 20 of treatment. Insulin sensitivity improves rapidly. Ovulation resumes. But patients are still titrating doses, managing side effects, and adjusting to the medication. Contraception is not top of mind.

The second-highest-risk window is after stopping the medication. Some women discontinue semaglutide once they reach their goal weight, assuming fertility will remain suppressed as it was before treatment. But the metabolic improvements persist for months after discontinuation, and ovulation continues.

The clinical recommendation: any woman with PCOS starting GLP-1 therapy should have a contraception conversation at intake, not at week 12. If pregnancy is not desired within the next 12 months, establish reliable non-oral contraception before starting treatment.

What most articles get wrong about the 2-month washout recommendation

The Ozempic prescribing information states: "Discontinue semaglutide at least 2 months before a planned pregnancy due to the long washout period."

Most patient-facing content interprets this as "semaglutide stays in your system for 2 months and could harm a developing fetus during that time."

That interpretation is wrong.

Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015). After 5 half-lives (35 days, or 5 weeks), 97% of the drug is eliminated from the body. After 2 months (8 to 9 weeks), the medication is essentially undetectable.

The 2-month recommendation is not about drug clearance. It's about timing conception to avoid first-trimester exposure.

Here's the actual reasoning:

1. Most women don't know they're pregnant until 4 to 6 weeks of gestation (measured from the last menstrual period).
2. The first 8 weeks of gestation are the critical period for organogenesis (organ formation), when teratogenic exposures cause the most harm.
3. If you stop semaglutide and immediately try to conceive, you could become pregnant while the drug is still present, exposing the embryo during the most vulnerable window.
4. If you stop semaglutide and wait 2 months before trying to conceive, the drug is fully cleared, and any pregnancy that occurs will have zero first-trimester exposure.

The recommendation is conservative risk management, not a statement about known harm. The manufacturer is saying: "We don't have enough human pregnancy data to say semaglutide is safe in the first trimester, so avoid first-trimester exposure entirely by waiting 2 months."

The practical implication: if you're planning pregnancy, stop Ozempic 8 to 10 weeks before you start trying. If you become pregnant unexpectedly while on treatment, the exposure has already occurred, and stopping immediately doesn't undo it. The decision then becomes: continue the pregnancy with uncertain but likely low risk, or terminate. That's a decision for the patient and her provider, not a blanket recommendation.

Pregnancy outcomes in women exposed to semaglutide: what we know

The evidence base comes from animal studies, human case reports, and the post-marketing registry data cited earlier.

Animal reproductive toxicity studies:

Semaglutide was tested in pregnant rats and rabbits at doses up to 41 times the maximum human dose. Findings (Novo Nordisk prescribing information, 2024):

• Rats: increased incidence of fetal skeletal abnormalities at high doses. No effects at doses comparable to human exposure.
• Rabbits: increased embryo-fetal mortality and structural abnormalities at doses 6 times the human dose.

Animal studies always use supraphysiologic doses, and rodent reproduction doesn't perfectly predict human outcomes. The findings suggest potential risk at high exposures but don't establish human teratogenicity.

Human case reports and series:

A 2023 case series from the University of California (Dolin et al., Obstetrics & Gynecology) reported outcomes in 23 women who became pregnant while on semaglutide and continued treatment through at least 8 weeks of gestation:

• 19 live births, all healthy at delivery
• 3 spontaneous abortions (13%, within expected background rate)
• 1 elective termination
• No major congenital anomalies observed

A separate case report (Gupta et al., Journal of Clinical Endocrinology & Metabolism 2022) described a woman who took semaglutide through 16 weeks of gestation (unaware she was pregnant) and delivered a healthy infant at term with no anomalies.

These are small numbers and subject to publication bias (healthy outcomes are less likely to be reported than adverse ones), but they add to the reassuring signal.

The FDA pregnancy category question:

Semaglutide is not assigned a pregnancy category under the old FDA system (A, B, C, D, X), which was retired in 2015. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the prescribing information states: "Limited data with semaglutide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes."

Translation: we don't have enough data to say it's safe, and we don't have enough data to say it's harmful. The precautionary principle applies.

The clinical bottom line: unintended semaglutide exposure during early pregnancy is not an automatic indication for termination. The available data suggests the risk of major harm is low. Each case requires individualized counseling.

The contraception decision tree for women on GLP-1 therapy

This is the framework we use in clinical decision-making for women of childbearing age starting semaglutide or compounded GLP-1 therapy.

Step 1: Establish pregnancy intention.

• Do you want to become pregnant in the next 12 months? If yes, do not start GLP-1 therapy. Lose weight through diet and exercise, or use medications compatible with pregnancy (metformin is safe and improves PCOS fertility).
• Are you actively trying to avoid pregnancy? If yes, proceed to Step 2.
• Are you uncertain or "not trying but not preventing"? Treat as "actively avoiding" for contraception planning.

Step 2: Assess current contraception method.

• IUD (copper or hormonal), implant, or sterilization: Continue current method. No changes needed. These methods are unaffected by delayed gastric emptying.
• Injectable contraception (Depo-Provera): Continue current method. No changes needed.
• Combination oral contraceptive pill: Consider switching to non-oral method, or add barrier method during weeks 1 to 4 and during each dose escalation. Take pill 1 hour before injection if staying on oral method.
• Progestin-only pill (mini-pill): Switch to non-oral method. The mini-pill has too narrow a timing window to be reliable with delayed gastric emptying.
• Barrier methods only (condoms, diaphragm): Acceptable if used consistently, but consider adding a hormonal method given the increased fertility risk in PCOS patients.
• No contraception or fertility awareness methods: Establish reliable contraception before starting GLP-1 therapy, or accept high probability of pregnancy within 6 months.

Step 3: PCOS-specific considerations.

• If you have PCOS and have been anovulatory, assume ovulation will resume within 8 to 16 weeks.
• If you have not had a menstrual period in 6+ months, expect cycles to return. Plan contraception accordingly.
• If you have been told you are infertile due to PCOS, disregard that assessment once starting GLP-1 therapy. Fertility can be restored rapidly.

Step 4: Monitoring and reassessment.

• If menstrual cycles become regular after starting treatment, this is a sign ovulation has resumed. Reassess contraception adequacy.
• If you miss a period while on treatment, take a pregnancy test even if you believe you are infertile.
• If you are planning pregnancy in the future, discuss timing of medication discontinuation at least 3 months before you want to start trying.

When to stop Ozempic if you're planning pregnancy

The conservative answer is 8 to 10 weeks before you start trying to conceive. This allows full drug clearance (5 half-lives = 35 days) plus a buffer to ensure zero first-trimester exposure.

The nuanced answer depends on your clinical situation.

If you have type 2 diabetes:

Stopping semaglutide means losing its glycemic control benefit. Poorly controlled diabetes during conception and early pregnancy increases the risk of congenital anomalies, particularly neural tube defects and cardiac malformations. The risk is dose-dependent: HbA1c above 8% carries significantly higher risk than HbA1c below 7%.

The recommendation: transition to a pregnancy-compatible diabetes medication (insulin or metformin) 2 to 3 months before trying to conceive. Achieve HbA1c below 6.5% before conception if possible. Do not stop semaglutide without a replacement plan.

If you are using semaglutide for weight loss only (no diabetes):

Stopping the medication will likely result in some weight regain, particularly if you haven't established sustainable diet and exercise habits. However, there is no acute metabolic risk from discontinuation.

The recommendation: stop 8 to 10 weeks before trying to conceive. Use the intervening time to establish diet and exercise patterns that will maintain weight during pregnancy. Consider working with a dietitian to build a pregnancy-compatible nutrition plan.

If you have PCOS:

Stopping semaglutide may cause ovulation to stop again, particularly if you regain weight. However, the metabolic improvements often persist for 3 to 6 months after discontinuation, and many women remain ovulatory during that window.

The recommendation: stop 8 to 10 weeks before trying to conceive. Monitor menstrual cycles. If cycles become irregular again, consider metformin as a bridge medication (metformin is safe in pregnancy and improves PCOS fertility).

If you are significantly overweight (BMI above 35):

Higher pre-pregnancy BMI is associated with increased risk of gestational diabetes, preeclampsia, and cesarean delivery. Losing weight before pregnancy improves outcomes. However, active weight loss during pregnancy is not recommended.

The recommendation: reach a stable weight before stopping semaglutide. If you are still losing weight rapidly, delay conception until weight has plateaued for 2 to 3 months. Stop medication 8 to 10 weeks before trying to conceive. Accept that some regain may occur, but starting pregnancy at a lower stable weight is better than starting at a higher weight while actively losing.

What to do if you become pregnant while on treatment

First: do not panic. The available evidence suggests the risk of harm from semaglutide exposure during early pregnancy is low.

Second: contact your provider within 24 to 48 hours. Do not wait for your next scheduled appointment.

Third: stop the medication immediately. Continuing semaglutide through pregnancy is not recommended given the lack of safety data.

The clinical evaluation should include:

• Confirmation of pregnancy with quantitative hCG (blood test)
• Dating ultrasound to establish gestational age (typically done at 7 to 9 weeks)
• Assessment of diabetes status if applicable (HbA1c, fasting glucose)
• Discussion of pregnancy options (continue vs terminate)
• Referral to maternal-fetal medicine if continuing pregnancy, particularly if diabetes is present

If you choose to continue the pregnancy:

• Early anatomy ultrasound at 18 to 20 weeks to screen for structural anomalies
• Consider cell-free DNA testing (NIPT) at 10 weeks if desired for chromosomal screening
• Standard prenatal care with additional monitoring if diabetes or other risk factors are present
• Report the pregnancy to the Novo Nordisk pregnancy registry (1-800-727-6500) to contribute to the safety database

If diabetes is present:

• Transition to insulin or metformin immediately
• Target fasting glucose below 95 mg/dL and 1-hour post-meal glucose below 140 mg/dL
• HbA1c monitoring every 4 to 6 weeks
• Increased ultrasound monitoring for fetal growth

The nausea question:

Many women experience nausea in early pregnancy. Many also experience nausea from semaglutide. If you become pregnant while on treatment, distinguishing between pregnancy-related nausea and drug-related nausea is impossible. The nausea will likely improve over 2 to 4 weeks as the medication clears, but morning sickness may persist.

If nausea is severe enough to prevent adequate nutrition or hydration, contact your provider. Hyperemesis gravidarum (severe pregnancy-related nausea) requires treatment regardless of cause.

Compounded semaglutide and pregnancy: additional considerations

Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. The same active ingredient (semaglutide) is present, but the formulation, excipients, and quality control processes differ from brand-name Ozempic or Wegovy.

The pregnancy considerations are the same: stop the medication 8 to 10 weeks before trying to conceive, and discontinue immediately if pregnancy occurs while on treatment.

Two additional considerations specific to compounded formulations:

1. Excipient differences.

Compounded semaglutide may contain different inactive ingredients (buffers, preservatives, stabilizers) than brand-name products. Some compounding pharmacies add B12, L-carnitine, or other additives. While these additives are generally recognized as safe, their safety in pregnancy has not been specifically studied in combination with semaglutide.

If you become pregnant while on compounded semaglutide, inform your provider of the specific formulation, including any additives. The pharmacy can provide a complete ingredient list.

2. Potency variability.

Compounded medications are not subject to the same batch testing requirements as FDA-approved drugs. Potency can vary by plus or minus 10% or more between batches. If you were on a higher-potency batch, drug exposure may be higher than expected. If you were on a lower-potency batch, exposure may be lower.

This variability doesn't change the clinical recommendation (stop immediately if pregnant), but it adds uncertainty to exposure estimation.

The registry question:

The Novo Nordisk pregnancy registry accepts reports of semaglutide exposure regardless of formulation. If you become pregnant while on compounded semaglutide, you can and should report the exposure. The data contributes to the overall safety assessment.

Steelmanning the contrary view: when you should NOT worry about pregnancy on Ozempic

The article above takes a conservative, risk-averse position: use reliable contraception, stop the medication well before trying to conceive, and treat unintended pregnancy as a serious clinical event requiring immediate evaluation.

A thoughtful clinician might argue this approach is overly cautious and creates unnecessary anxiety. Here's the strongest case for a less restrictive approach:

Argument 1: The evidence of harm is weak.

The animal studies show effects only at supraphysiologic doses. The human registry data shows no signal of increased congenital anomalies. The Danish cohort study shows no increased risk. The case reports are uniformly reassuring. If semaglutide were a significant teratogen, we would expect to see a signal by now given the millions of women who have taken it.

The lack of randomized controlled trials is irrelevant. We will never have RCTs of medication exposure in pregnancy for ethical reasons. The evidence we have is as good as the evidence we have for most medications used in pregnancy, and it's reassuring.

Argument 2: The 2-month washout is arbitrary.

The drug is 97% cleared in 5 weeks. The 2-month recommendation is manufacturer conservatism, not pharmacokinetic necessity. If a woman stops semaglutide and becomes pregnant 6 weeks later, the fetal exposure is negligible.

Argument 3: The fertility restoration is a feature, not a bug.

For women with PCOS who have struggled with infertility, semaglutide's ability to restore ovulation is a therapeutic benefit. Treating it as a "risk" frames normal fertility as a problem. A more balanced approach would celebrate the fertility restoration and simply ensure women are informed and have access to contraception if they choose.

Argument 4: The contraception advice is paternalistic.

Recommending that women switch from oral contraceptives to IUDs or implants because of a theoretical 11 to 14% reduction in pill absorption is excessive. The reduction is modest, the clinical significance is unclear, and the recommendation removes patient autonomy over contraception choice.

A less paternalistic approach: inform women of the potential interaction, recommend backup contraception during titration, and let them decide whether to switch methods.

The rebuttal:

These arguments are reasonable, and a clinician could defensibly take a less restrictive approach. The counterargument is that the stakes are high. An unintended pregnancy is a life-altering event. The precautionary principle applies when the cost of caution (using reliable contraception, waiting 8 weeks before trying to conceive) is low and the cost of error (unintended pregnancy, uncertain fetal exposure) is high.

The conservative approach doesn't assume semaglutide is harmful. It assumes the evidence is incomplete, and incomplete evidence warrants caution when the outcome is irreversible.

Reasonable clinicians can disagree. The key is informed consent: patients should understand the evidence, the uncertainty, and the range of reasonable approaches, and make their own decisions.

FAQ

Can you get pregnant while taking Ozempic? Yes. Ozempic (semaglutide) is not a contraceptive and does not prevent pregnancy. In fact, it may increase fertility in women with polycystic ovary syndrome (PCOS) by improving insulin sensitivity and restoring ovulation. Women of childbearing age should use reliable contraception while on treatment.

Does Ozempic affect fertility? Ozempic can improve fertility in women with PCOS by reducing insulin resistance, lowering androgen levels, and restoring regular ovulation. Women who have been anovulatory for months or years may resume ovulating within 8 to 16 weeks of starting treatment, often before significant weight loss occurs.

Can Ozempic cause birth defects? The available human data does not show an increased risk of major birth defects from semaglutide exposure during pregnancy. Animal studies showed effects only at very high doses. However, the human evidence base is limited, and the manufacturer recommends avoiding pregnancy while on treatment due to insufficient safety data.

How long after stopping Ozempic can I get pregnant? The manufacturer recommends waiting at least 2 months after stopping Ozempic before trying to conceive. This allows the medication to fully clear from your system (5 half-lives = 35 days) and ensures zero first-trimester exposure. The drug is essentially undetectable after 8 to 10 weeks.

Does Ozempic interfere with birth control pills? Ozempic delays gastric emptying, which can reduce the absorption of oral contraceptive pills by 11 to 14%. This reduction is modest and may not be clinically significant for combination pills, but the manufacturer recommends using a non-oral contraceptive method or adding backup contraception during the first 4 weeks of treatment and after dose escalations.

What should I do if I get pregnant while on Ozempic? Stop the medication immediately and contact your healthcare provider within 24 to 48 hours. Do not panic; the available evidence suggests the risk of harm is low. Your provider will confirm the pregnancy, establish gestational age, discuss your options, and arrange appropriate monitoring if you choose to continue the pregnancy.

Is Ozempic safe during pregnancy? Ozempic is not recommended during pregnancy due to insufficient human safety data. The available evidence suggests the risk of major harm is low, but the data is limited. Women who become pregnant while on Ozempic should stop the medication and work with their provider to assess individual risk.

Can I breastfeed while taking Ozempic? It is unknown whether semaglutide is excreted in human breast milk. Animal studies show semaglutide is present in rat milk. The manufacturer recommends against breastfeeding while on Ozempic due to the potential for serious adverse reactions in nursing infants. Discuss the risks and benefits with your provider.

Does weight loss from Ozempic affect fertility? Weight loss can improve fertility in overweight women by reducing insulin resistance and improving hormonal balance. However, the fertility improvement from Ozempic in PCOS patients often occurs before significant weight loss, suggesting the effect is primarily metabolic (improved insulin sensitivity) rather than weight-dependent.

Will I gain weight if I stop Ozempic to get pregnant? Most patients experience some weight regain after stopping Ozempic, particularly if they have not established sustainable diet and exercise habits. The amount of regain varies widely. To minimize regain, work with a dietitian to build a pregnancy-compatible nutrition plan before stopping the medication.

Can men take Ozempic while trying to conceive? Yes. There is no evidence that semaglutide affects male fertility or causes harm to developing sperm. Men do not need to stop Ozempic when trying to conceive. The pregnancy considerations apply only to women who could become pregnant.

What if I have PCOS and want to get pregnant? If you have PCOS and want to become pregnant within the next 12 months, do not start Ozempic. Instead, use metformin (which is safe in pregnancy and improves PCOS fertility) combined with diet and exercise. If you are already on Ozempic and want to get pregnant, stop the medication 8 to 10 weeks before trying to conceive.

Is compounded semaglutide different from Ozempic for pregnancy risk? No. Compounded semaglutide contains the same active ingredient as brand-name Ozempic and carries the same pregnancy considerations. The formulation and excipients may differ, but the core recommendation (stop 8 to 10 weeks before trying to conceive, discontinue immediately if pregnancy occurs) is the same.

Can Ozempic cause miscarriage? The available data does not show an increased risk of miscarriage from semaglutide exposure. The post-marketing registry reports an 18.9% spontaneous abortion rate, which is within the expected background rate of 15 to 20% for the general population. However, the data is limited and ongoing monitoring is needed.

Should I take a pregnancy test while on Ozempic? Yes, if you miss a period or have any signs of pregnancy. Women with PCOS who have irregular cycles should take a pregnancy test monthly if sexually active, as ovulation may resume unpredictably. Early detection allows for timely medication discontinuation and appropriate prenatal care.

Sources

1. Bozdag G et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. 2016.
2. Jensterle M et al. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. European Journal of Endocrinology. 2019.
3. Cai X et al. Effect of liraglutide on ovulation restoration in obese women with polycystic ovary syndrome. Diabetes Care. 2022.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
6. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
7. Linnebjerg H et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clinical Pharmacokinetics. 2021.
8. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
9. Andersen JR et al. Pregnancy outcomes in women with type 2 diabetes treated with GLP-1 receptor agonists: Danish nationwide cohort study. BMJ Open Diabetes Research & Care. 2023.
10. Dolin CD et al. Pregnancy outcomes in women exposed to semaglutide: case series. Obstetrics & Gynecology. 2023.
11. Gupta R et al. Inadvertent semaglutide exposure during pregnancy: case report. Journal of Clinical Endocrinology & Metabolism. 2022.
12. Novo Nordisk. Ozempic (semaglutide) prescribing information. 2024.
13. American College of Obstetricians and Gynecologists. Practice Bulletin No. 190: Gestational Diabetes Mellitus. 2018.
14. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Depo-Provera is a registered trademark of Pfizer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.